866-997-4948(US-Canada Toll Free)

Victoza (Type 2 Diabetes) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Diabetes

No. of Pages : 47 Pages


Summary

GlobalDatas pharmaceuticals report, Victoza (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Victoza sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 2 business days (excluding weekends) of the purchase.

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Victoza including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Victoza including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Victoza in the US, EU5 and Japan
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19

6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 19
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Victoza 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 25
7.3.1 Monotherapy 25
7.3.2 Combination Therapy 26
7.4 Approval History of Victoza 30
7.5 Factors Affecting Sales of Victoza 30
7.5.1 Association of Victoza with Weight Loss among Patients 30
7.5.2 Competition from Once-weekly Drugs 31
7.5.3 Victoza Giving Competition to Byetta 31
7.5.4 Patient Satisfaction Significantly Higher with Injectable Victoza than Oral Januvia 31
7.5.5 Boxed Warning of Victoza with Risk of Thyroid C-Cell Tumors 31
7.6 Drug Evaluation 31
7.6.1 Drug Risk Benefit Score 31
7.6.2 Intensity of Competition 32
7.7 Sales Forecasts 33
7.7.1 Target Patient Pool for Victoza 33
7.7.2 Dosing 33
7.7.3 Market Penetration 33
7.7.4 Annual Cost of Therapy 34
7.7.5 Sales Projections of Victoza 35

8 Diabetes Market: Appendix 44
8.1 Market Definitions 44
8.2 List of Abberiviations 44
8.3 Research Methodology 44
8.3.1 Coverage 45
8.3.2 Secondary Research 45
8.3.3 Forecasting 45
8.3.4 Net Penetration of Drug 46
8.3.5 Net Annual Dosing 46
8.3.6 Annual Cost of Therapy 46
8.3.7 Primary Research 46
8.3.8 Expert Panels 46
8.4 Drug Sales Estimates Model 47
8.5 Contact Us 47
8.6 Disclaimer 47
8.7 Sources 47

List of Table


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: Results of LEAD 3 Study of Victoza Used as Monotherapy 26
Table 10: Results of 26-Week Controlled Trial of Victoza Used as Add-on to Metformin 27
Table 11: Results of 26-Week Controlled Trial of Victoza Used as Add-on to Sulfonylurea 28
Table 12: Results of 26-Week Controlled Trial of Victoza Used as an Add-on to Metformin and Sulfonylurea 29
Table 13: Results of 26-Week Controlled Trial of Victoza Used as an Add-on to Metformin and Thiazolidinedione 30
Table 14: Approval of Victoza by Region 30
Table 15: Drug Risk Benefit Score of Victoza 31
Table 16: Annual Cost of Therapy of Victoza 34
Table 17: Victoza, Type 2 Diabetes, Global, Sales Estimates ($m), 20092020 35
Table 18: Victoza, Type 2 Diabetes, The US, Sales Estimates ($m), 20102020 36
Table 19: Victoza, Type 2 Diabetes, The UK, Sales Estimates ($m), 20092020 37
Table 20: Victoza, Type 2 Diabetes, France, Sales Estimates ($m), 20102020 38
Table 21: Victoza, Type 2 Diabetes, Germany, Sales Estimates ($m), 20092020 39
Table 22: Victoza, Type 2 Diabetes, Italy, Sales Estimates ($m), 20102020 40
Table 23: Victoza, Type 2 Diabetes, Spain, Sales Estimates ($m), 20102020 41
Table 24: Victoza, Type 2 Diabetes, Japan, Sales Estimates ($m), 20102020 42

List of Chart


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylurea 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Market Share as per Classes (%), 2010 24
Figure 12: Victoza, Type 2 Diabetes, Global, Sales Estimates ($m), 20092020 35
Figure 13: Victoza, Type 2 Diabetes, The US, Sales Estimates ($m), 20102020 36
Figure 14: Victoza, Type 2 Diabetes, The UK, Sales Estimates ($m), 20092020 37
Figure 15: Victoza, Type 2 Diabetes, France, Sales Estimates ($m), 20102020 38
Figure 16: Victoza, Type 2 Diabetes, Germany, Sales Estimates ($m), 20092020 39
Figure 17: Victoza, Type 2 Diabetes, Italy, Sales Estimates ($m), 20102020 40
Figure 18: Victoza, Type 2 Diabetes, Spain, Sales Estimates ($m), 20102020 41
Figure 19: Victoza, Type 2 Diabetes, Japan, Sales Estimates ($m), 2010-2020 42
Figure 20: Victoza, Type 2 Diabetes, Global, Sales Distribution (%), 2020 43

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *